Financial Performance - Operating revenue for the reporting period was CNY 625,133,254.15, an increase of 6.87% year-on-year[7] - Net profit attributable to shareholders of the listed company was CNY 1,525,587.26, a significant recovery from a loss of CNY 19,824,206.74 in the same period last year[7] - Basic and diluted earnings per share were both CNY 0.005, recovering from a loss of CNY 0.03 per share in the same period last year[7] - Total operating revenue for Q1 2015 was CNY 625,133,254.15, an increase of 6.5% compared to CNY 584,934,101.94 in the same period last year[27] - Net profit for Q1 2015 was CNY 3,499,058.17, a significant recovery from a net loss of CNY 19,270,214.82 in the previous year[28] - The operating profit has improved to ¥13,063,322.78 from a loss of ¥4,962,867.66 in the previous period[30] - The total comprehensive income for the current period is ¥12,470,091.43, compared to a loss of ¥5,080,461.01 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,047,210,345.57, a decrease of 0.92% compared to the end of the previous year[7] - The company's total liabilities amounted to CNY 2,540,342,870.87, down from CNY 2,580,702,321.26, showing a decrease in financial obligations[19] - Non-current liabilities totaled CNY 722,943,207.00, an increase from CNY 687,008,865.88, reflecting changes in long-term payables[19] - The company's retained earnings improved from a deficit of CNY 9,760,927.71 to a deficit of CNY 6,869,185.36, indicating a reduction in accumulated losses[20] - The company's total assets at the end of the reporting period were CNY 3,618,516,424.31, slightly up from CNY 3,611,542,004.99 at the beginning of the year[24] - The company's total liabilities decreased to CNY 2,117,642,298.56 from CNY 2,123,137,970.67, indicating a reduction in financial obligations[24] Cash Flow - Cash flow from operating activities was CNY 35,716,962.98, down 23.66% compared to the previous year[7] - The cash flow from operating activities has generated a net amount of ¥35,716,962.98, down from ¥46,787,519.83 in the previous period[34] - Operating cash flow for Q1 2015 was CNY 35,427,741.29, a decrease of 19% compared to CNY 43,746,735.64 in the same period last year[35] - Total cash inflow from operating activities was CNY 427,755,668.16, slightly up from CNY 427,551,232.53 year-over-year[35] - Cash outflow from operating activities increased to CNY 392,327,926.87 from CNY 383,804,496.89, representing a rise of approximately 2%[35] - Net cash flow from investing activities was negative CNY 43,964,163.31, worsening from negative CNY 4,082,214.10 in the previous year[35] - Cash inflow from financing activities totaled CNY 175,013,000.00, up from CNY 150,039,872.00, marking a growth of about 17%[36] - Net cash flow from financing activities improved to CNY 12,131,676.50 from negative CNY 87,544,545.16 year-over-year[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 75,477[12] - The largest shareholder, Shandong Provincial Government State-owned Assets Supervision and Administration Commission, held 24.59% of the shares[12] Other Financial Metrics - The weighted average return on net assets improved to 0.21% from -1.24% year-on-year[7] - The company reported non-recurring gains of CNY 1,366,155.09 during the period[9] - The fair value of financial assets measured at fair value and recognized in profit or loss increased by 37.27% from CNY 1,768,740.00 to CNY 2,428,020.00 due to the rise in the fair value of trading financial assets[14] - Prepayments decreased by 29.93% from CNY 48,185,235.60 to CNY 33,761,962.11 primarily due to a reduction in prepaid goods[14] - Tax payable increased by 42.72% from CNY 9,264,824.03 to CNY 13,222,949.27 mainly due to an increase in value-added tax payable[14] - Interest payable surged by 294.15% from CNY 1,912,208.04 to CNY 7,536,972.53 as a result of increased unpaid loan interest[14] - Operating tax and surcharges rose by 68.66% from CNY 2,334,867.72 to CNY 3,937,966.98 due to higher value-added tax accruals[15] - Investment income decreased by 32.32% from CNY 2,406,966.72 to CNY 1,629,032.03 primarily due to reduced investment income from joint ventures[15] - The company's cash and cash equivalents decreased slightly to CNY 379,743,632.32 from CNY 389,115,701.88 at the beginning of the year[22] - The ending balance of cash and cash equivalents was CNY 354,133,632.32, down from CNY 382,929,443.00 in the previous year[36] - Cash inflow from other operating activities increased to CNY 2,279,205.79 from CNY 1,267,977.88, a growth of approximately 80%[35] - Total cash outflow for investing activities was CNY 81,377,747.08, significantly higher than CNY 20,082,214.10 in the same period last year[35] - The impact of exchange rate changes on cash and cash equivalents was CNY 672,675.96, compared to CNY 156,629.32 in the previous year[36]

2014 年第三季度报告 山东鲁抗医药股份有限公司 2014 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2014 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | | | | 减(%) | | 总资产 | 3,995,332,098.14 | 4,074,763,953.85 | -1.95 | | 归属于上市公司 | 1,449,722,644.90 | 1,527,517,109.66 | -5.09 | ...

Financial Performance - The company's operating revenue for the first half of 2014 was CNY 1,157,803,034.63, a decrease of 1.32% compared to the same period last year[15]. - The net profit attributable to shareholders was a loss of CNY 50,018,651.40, representing a decline of 108.60% year-on-year[15]. - The total revenue for the company was CNY 1,141,916,060.05, representing a decrease of 0.97% compared to the previous year[21]. - The company reported a net profit margin improvement, with net profit for the first half of 2014 showing positive trends compared to the same period last year[53]. - The net profit for the current period was CNY -24,139,143.85, reflecting a significant decline compared to the previous year's profit[73]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to CNY 124,427,100.94, up 467.18% from the previous year[15]. - The net cash flow from operating activities for the first half of 2014 was CNY 106,142,464.66, a significant increase compared to CNY 1,440,498.65 in the same period last year[64]. - Total cash inflow from operating activities reached CNY 889,145,045.47, up from CNY 832,523,640.63 year-on-year[64]. - Cash and cash equivalents at the end of the reporting period amounted to 624,106,727.98 RMB, up from 589,224,369.94 RMB, indicating an increase of about 5.5%[46]. - The ending balance of cash and cash equivalents was CNY 424,854,124.54, slightly down from CNY 437,164,410.77 at the end of the previous year[66]. Assets and Liabilities - The company's total assets as of June 30, 2014, were CNY 4,113,874,725.00, an increase of 0.96% compared to the end of the previous year[15]. - Current liabilities totaled CNY 1,771,304,781.15, an increase from CNY 1,684,124,523.92, reflecting a rise of about 5.16%[48]. - Total liabilities reached CNY 2,531,408,514.57, compared to CNY 2,440,004,098.73, indicating an increase of around 3.75%[48]. - Owner's equity decreased to CNY 1,582,466,210.43 from CNY 1,634,759,855.12, reflecting a decline of about 3.20%[48]. Revenue Breakdown - Domestic revenue accounted for CNY 897,415,563.29, with a growth of 1.08%, while international revenue was CNY 244,500,496.76, showing a decline of 7.82%[23]. - The revenue from antibiotic raw materials was CNY 119,104,111.61, with a gross margin of 23.91%, reflecting an increase of 4.47 percentage points[21]. - The revenue from veterinary antibiotics reached CNY 284,261,095.14, with a gross margin of 4.98%, which is an increase of 1.59 percentage points[21]. Research and Development - Research and development expenses rose to CNY 45,964,025.52, reflecting a 14.40% increase year-on-year[18]. - The company is investing in research and development for new products and technologies to maintain competitive advantage in the pharmaceutical industry[172]. Shareholder Information - The total number of shareholders at the end of the reporting period was 94,476[37]. - The largest shareholder, Shandong Provincial Government State-owned Assets Supervision and Administration Commission, holds 24.59% of shares, totaling 142,997,400 shares[37]. - The second largest shareholder, China Capital (Holdings) Limited, holds 9.98% of shares, totaling 58,049,866 shares[37]. Corporate Strategy and Future Plans - The company plans to accelerate product structure adjustments and improve technology and product quality in the second half of 2014[16]. - The company aims to enhance management efficiency and promote market expansion through innovative business models[19]. - The company plans to expand its market presence and invest in new product development to drive future growth[53]. - The company is actively pursuing mergers and acquisitions to enhance its market share and product offerings in the pharmaceutical sector[171]. Inventory and Receivables Management - The total accounts receivable at the end of the period amounted to CNY 560,504,184, with a bad debt provision of CNY 116,608,749.05, representing a provision ratio of 20.81%[182]. - The aging analysis shows that 85.61% of receivables are within one year, indicating a strong short-term collection outlook[197]. - The company has established clear criteria for assessing the impairment of available-for-sale financial assets, recognizing losses when fair value declines significantly[115]. Accounting Policies and Compliance - The financial report was approved by the company's seventh board of directors on August 28, 2014[89]. - The company adheres to the accounting standards issued by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[92]. - The company has confirmed that there are no changes in accounting policies or estimates for the reporting period[163].

一、 重要提示 山东鲁抗医药股份有限公司 600789 2014 年第一季度报告 | 目录 | | --- | | 一、 | 重要提示 1 | | --- | --- | | 二、 | 公司主要财务数据和股东变化 2 | | 三、 | 重要事项 5 | | 四、 | 附录 6 | 600789 山东鲁抗医药股份有限公司 2014 年第一季度报告 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 | 公司负责人姓名 | 杜建方 | | --- | --- | | 主管会计工作负责人姓名 | 李红 | | 会计机构负责人（会计主管人员）姓名 | 李全翼 | 公司负责人杜建方、主管会计工作负责人李红及会计机构负责人（会计主管人员）李全翼保 证季度报告中财务报表的真实、准确、完整。 1.4 公司第一季度报告中的财务报表未经审计。 1 600789 山东鲁抗医药股份有限公司 2014 年第一季度报告 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单 ...

Financial Performance - The company's operating revenue for 2013 was CNY 2,210,685,342.55, a decrease of 5.5% compared to CNY 2,339,454,261.36 in 2012[21] - The net profit attributable to shareholders for 2013 was CNY 10,857,943.47, a significant recovery from a loss of CNY 133,834,252.34 in 2012[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -169,850,730.77, worsening from CNY -151,188,382.44 in 2012, reflecting a 12.34% increase in losses[21] - The total revenue for the year was CNY 2,194,708,977.50, representing a decrease of 4.16% compared to the previous year[41] - The company reported a net profit margin improvement, with retained earnings rising to CNY 115,453,602.78 from CNY 104,595,659.31, an increase of approximately 10.4%[121] - The net profit for the year was CNY 94,137,236.17, compared to a loss of CNY 133,834,252.34 in the previous year, indicating a significant turnaround in profitability[151] Cash Flow and Investments - The net cash flow from operating activities increased by 122.65% to CNY 256,497,339.00 from CNY 115,202,032.97 in 2012[21] - The net cash flow from operating activities increased by 122.65% compared to the previous year, primarily due to an increase in government subsidies received[37] - The net cash flow from investing activities improved by 39.91% year-on-year, mainly due to reduced capital expenditures and the disposal of subsidiary equity[38] - The net cash flow from financing activities decreased by 41.68% compared to the previous year, primarily due to an increase in debt repayment[38] - The company reported a net cash flow from operating activities of CNY 243,807,858.35, an increase from CNY 90,385,165.16 in the previous year[138] Assets and Liabilities - The total assets at the end of 2013 were CNY 4,074,763,953.85, representing a 2.25% increase from CNY 3,985,171,290.49 in 2012[21] - Current liabilities decreased to CNY 1,684,124,523.92 from CNY 1,819,896,308.49, a reduction of about 7.4%[120] - Non-current liabilities rose to CNY 755,879,574.81, compared to CNY 558,317,413.63, indicating an increase of approximately 35.4%[121] - The total liabilities increased to CNY 2,440,004,098.73 from CNY 2,378,213,722.12, an increase of approximately 2.6%[121] Shareholder Information - The total number of shares remains at 581,575,475, with no changes in the shareholding structure[72] - The largest shareholder, Shandong Provincial Government State-owned Assets Supervision and Administration Commission, holds 24.59% of shares, totaling 142,997,400 shares[78] - The total number of shareholders at the end of the reporting period was 102,329, an increase from 95,673 in the previous reporting period[77] Management and Governance - The company has maintained a stable board composition with no changes in shareholding among directors during the reporting period[83] - The management team is committed to maintaining operational stability and pursuing growth opportunities in the pharmaceutical market[85] - The company has established a sound corporate governance structure, complying with the requirements of the China Securities Regulatory Commission[100] - The board of directors has held 7 meetings during the reporting period, with 2 being in-person meetings[105] Operational Highlights - The company has maintained its main business operations without any changes since its listing[17] - The company optimized its product and market structure, focusing on profitable products while reducing production of loss-making products[27] - The company successfully passed the new GMP certification for its human oral solid preparations, powder injections, and sterile raw materials[28] - The company is engaged in the production of antibiotics and related pharmaceutical products, maintaining its focus on the antibiotic manufacturing industry[162] Risk Management - The company has not faced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[6] - The company has not experienced any administrative penalties or public reprimands from the China Securities Regulatory Commission during the reporting period[69] - The supervisory board found no issues with the company's risk management during the reporting period[108] Research and Development - Research and development expenses totaled CNY 112.88 million, accounting for 5.11% of operating revenue and 6.90% of net assets[36] - The company has established a strong technical advantage with a national-level enterprise technology center and collaborations with several universities[47] Financial Reporting and Compliance - The company maintained a standard unqualified audit opinion on its financial statements for the year ended December 31, 2013, confirming the fair presentation of its financial position[116] - The company adheres to the accounting standards set by the Ministry of Finance, ensuring transparency and accuracy in its financial reporting[166]